Determinants of outcome in patients with chronic ischemic left ventricular dysfunction undergone percutaneous coronary interventions

BMC Cardiovascular Disorders

Paolo G. Camici⁴  Antonio Colombo⁵  Ornella E. Rimoldi²  Isabella Scotti⁶  Francesco Arioli³  Francesco Moroni⁴  Azeem Latib⁴  Valentina Guida⁴  Enrico Ammirati¹ 

[1] Cardiothoracic Department, San Raffaele Scientific Institute and University, Via Olgettina 60, Milan,, 20132, Italy;CNR Institute of Clinical Physiology, Milan, Italy;A.O. Ospedale di Circolo di Busto Arsizio, Busto Arsizio, VA, Italy;IRCCS Ospedale San Raffaele and Vita-Salute University San Raffaele, Via Olgettina 60, Milan, 20132, Italy;EMO-GVM Centro Cuore Columbus, Milan, Italy;Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy

关键词: stress testing;    Percutaneous coronary intervention;    Coronary revascularization;    Heart failure;    Ischemic systolic left ventricular dysfunction;    Coronary artery disease;   

Others  :  1230186
DOI  :  10.1186/s12872-015-0126-x

 received in 2015-07-06, accepted in 2015-10-16,  发布年份 2015

【 摘 要 】

Background

Percutaneous coronary interventions (PCI) in patients with ischemic systolic left ventricular dysfunction (SLVD) are routinely performed although their impact on prognosis remains unclear.

Methods

We retrospectively evaluated 385 consecutive patients (76 % male, 66 ± 9 years) with SLVD (left ventricular ejection fraction [LVEF] ≤40 %) due to chronic coronary artery disease, who underwent PCI between 1999 and 2009, and explored clinical factors associated with higher risk of death or of a composite of death and hospitalization for acute decompensated heart failure (ADHF).

Results

The median follow-up was 28 months (inter-quartile range 14–46 months). Death and the composite outcome of death and hospitalization for ADHF occurred in 80 (21 %) and 109 (28 %) patients respectively (8.4 and 11.5 per 100 patient-years of follow-up). Insulin-dependent diabetes mellitus (IDDM), multivessel disease, LVEF < 35 %, symptoms of heart failure (HF) emerged both as independent predictors of death (adjusted hazard ratios [HR] 2.64; 1.92, 1.88 and 1.67 respectively) and composite outcome of death and hospitalization for ADHF (adjusted HR 2.22, 1.92, 1.79 and 1.94 respectively). Furthermore advanced age (HR = 1.03) emerged as independent predictors of death and having performed a stress test before PCI correlated with reduced number of deaths and ADHF hospitalizations (HR = 0.60). Of note, PCI significantly reduced the symptom of angina from 63.2 % at baseline to 16.3 % at the last follow up (p < 0.0001).

Conclusions

IDDM, symptoms of HF, multivessel disease and LVEF < 35 % appear to be associated with worse outcome patients with ischemic SLVD undergoing PCI, and may be taken into account for optimal risk stratification. On the other hand, performing a stress testing before PCI seems to be associated with a more favorable outcome.

【 授权许可】

   
2015 Ammirati et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, et al.: Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
• [2]Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62(16):e147-e239.
• [3]McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787-1847.
• [4]Ammirati E, Rimoldi OE, Camici PG: Is there evidence supporting coronary revascularization in patients with left ventricular systolic dysfunction? Circ J 2010, 75(1):3-10.
• [5]Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, Chattopadhyay S, Norell MS, Pennell DJ, Senior R: The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 2011, 13(2):227-233.
• [6]Ammirati E, Cristell N, Cianflone D, Vermi AC, Marenzi G, De Metrio M, Uren NG, Hu D, Ravasi T, Maseri A, et al.: Questing for circadian dependence in ST-segment-elevation acute myocardial infarction: a multicentric and multiethnic study. Circ Res 2013, 112(10):e110-e114.
• [7]Velazquez EJ, Bonow RO: Revascularization in severe left ventricular dysfunction. J Am Coll Cardiol 2015, 65(6):615-624.
• [8]Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A. et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med. 2011;364(17):1607-1616.
• [9]Velazquez EJ, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, O’Connor CM, Smith PK, Jones RH: Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. Ann Thorac Surg 2012, 93(2):523-530.
• [10]Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, Mock MB, Pettinger M, Robertson TL: Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990, 82(5):1629-1646.
• [11]Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, et al.: Authors/Task Force m: 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35(37):2541-2619.
• [12]Briguori C, Aranzulla TC, Airoldi F, Cosgrave J, Tavano D, Michev I, Montorfano M, Carlino M, Castelli A, Sangiorgi MG, et al.: Stent implantation in patients with severe left ventricular systolic dysfunction. Int J Cardiol 2009, 135(3):376-384.
• [13]Kunadian V, Pugh A, Zaman AG, Qiu W: Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and meta-analysis of 19 clinical studies. Coron Artery Dis 2012, 23(7):469-479.
• [14]Nagendran J, Norris CM, Graham MM, Ross DB, Macarthur RG, Kieser TM, Maitland AM, Southern D, Meyer SR, Investigators A: Coronary Revascularization for Patients With Severe Left Ventricular Dysfunction. Ann Thorac Surg 2013, 96(6):2038-2044.
• [15]Biondi-Zoccai G, Sheiban I, Moretti C, Palmerini T, Marzocchi A, Capodanno D, Tamburino C, Margheri M, Vecchi G, Sangiorgi G, et al.: Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clin Res Cardiol 2011, 100(5):403-411.
• [16]Lee DH, Jeong MH, Rhee JA, Choi JS, Lee KH, Lee MG, Sim DS, Park KH, Yoon NS, Yoon HJ, et al.: Predictors of long-term survival in acute coronary syndrome patients with left ventricular dysfunction after percutaneous coronary intervention. Korean Circ J 2012, 42(10):692-697.
• [17]Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, Shiomi H, Tanaka S, Sakata R: Investigators CR-KPCRC: Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions50 % (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 2014, 114(7):988-996.
• [18]Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH: Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008, 358(4):331-341.
• [19]Hlatky MA, Boothroyd DB, Baker L, Kazi DS, Solomon MD, Chang TI, Shilane D, Go AS: Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study. Ann Intern Med 2013, 158(10):727-734.
• [20]Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Jeong DS, Sung K, Kim WS, Lee YT, Gwon HC: Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction. Am J Cardiol 2013, 112(5):623-629.
• [21]Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, et al.: Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013, 381(9867):629-638.
• [22]Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, et al.: Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012, 367(25):2375-2384.
• [23]Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL: Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease. Circ Cardiovasc Interv 2015, 8(7):e002626.
• [24]Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, et al.: Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. N Engl J Med 2011, 364(17):1617-1625.
• [25]Ammirati E, Rimoldi OE, Camici PG: Myocardial viability in ischemic left ventricular dysfunction. N Engl J Med 2011, 365(5):471.
• [26]Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW, Cohen I, Germano G, Berman DS: Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011, 32(8):1012-1024.
• [27]Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Borges-Neto S, Farsky PS, Jones RH, et al.: Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013, 61(18):1860-1870.
• [28]Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, et al.: Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. J Am Coll Cardiol Intv 2014, 7(2):195-201.
• [29]Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008, 117(10):1283-1291.
• [30]Sedlis SP, Ramanathan KB, Morrison DA, Sethi G, Sacks J, Henderson W: Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol 2004, 94(1):118-120.